Peyronie's disease is a condition characterized by the development of fibrous scar tissue inside the penis, leading to curved, painful erections. While the exact cause of Peyronie's disease remains unclear, it is believed to result from penile trauma, either significant or micro-trauma, followed by an abnormal healing process. The management of Peyronie's disease can be challenging, and treatment success varies.

Surgical intervention is considered for cases where the penile curvature prevents satisfactory sexual intercourse and is typically reserved for the stable phase of the disease. Although surgery can be effective in correcting the curvature, it carries risks such as potential loss of penile length and erectile dysfunction.

Non-surgical treatments include oral medications, topical agents, and intralesional injections. The efficacy of these treatments can be unpredictable, and their success rates vary. Intralesional injections, such as verapamil, have been used to break down the scar tissue and reduce curvature. While these injections can be beneficial, they may cause discomfort during administration.

Recent studies have explored the use of iontophoresis, a non-invasive technique that uses electrical currents to enhance the transdermal delivery of medications. This method has been investigated for delivering corticosteroids directly to the penile plaques in Peyronie's disease. Iontophoresis may offer a less painful alternative to injections and has shown promising results in reducing plaque size and penile curvature.

PHYSION has developed a solution for the Electromotive Drug Administration (EMDA) that combines dexamethasone, a corticosteroid, with verapamil, an anticholinergic agent. This combination aims to reduce pain and fibrosis associated with Peyronie's disease plaques. The application of this EMDA solution could potentially offer a more comfortable and effective treatment option for patients suffering from this condition.